Aldasoro M, Medina P, Vila J M, Otero E, Martinez-León J B, Lluch S
Department of Physiology, University of Valencia, Spain.
J Vasc Surg. 1997 Apr;25(4):696-703. doi: 10.1016/s0741-5214(97)70297-0.
The goal of this study was to determine the effects of vasopressin and the selective V2-receptor agonist desmopressin on human saphenous veins, with special emphasis on endothelium-mediated responses.
Human saphenous vein segments were obtained from 35 patients undergoing coronary bypass surgery. Paired segments, one normal and the other deendothelized by gentle rubbing, were mounted for isometric recording of tension in organ baths. Concentration-response curves to vasopressin and desmopressin were determined in the presence and in the absence of either the V1-receptor antagonist d(CH2)5Tyr (Me)AVP (10(-6) mol/L), the V1-V2-receptor antagonist desGly-d(CH2)5D-Tyr(Et)ValAVP (10(-6) mol/L), indomethacin (10(-6) mol/L), or NG-nitro-L-arginine methyl ester hydrochloride (L-NAME, 10(-4) mol/L).
In vein rings under resting tension, vasopressin produced concentration-dependent, endothelium-independent contractions with a concentration of vasopressin producing half-maximal contractions (EC50) of 3.44 x 10(-8) mol/L. The vasopressin V1-receptor antagonist (10(-6) mol/L) displaced the control curve to vasopressin 9.86-fold to the right in a parallel manner. In precontracted vein rings previously treated with the V1-antagonist (10(-6) mol/L) vasopressin caused endothelium-dependent relaxations. This relaxation was reduced significantly by indomethacin (10(-6) mol/L) and unaffected by the V1-V2-receptor antagonist (10(-6) mol/L) or by L-NAME (10(-4) mol/L). Desmopressin caused endothelium-dependent relaxations in precontracted vein rings that were inhibited by the mixed V1-V2-receptor antagonist and by indomethacin, but not by the V1-antagonist or by pretreatment with L-NAME.
These observations indicate that vasopressin exerts contractile effects on human saphenous vein by V1-receptor stimulation. Vasopressin causes dilatation of human saphenous vein only if V1-receptor blockade is present. This relaxation appears to be mediated by the release of relaxant prostaglandins, probably derived from endothelial cells, and is independent of V2-receptor stimulation or release of nitric oxide. Desmopressin elicits relaxation that is largely dependent on V2-receptor stimulation, which may bring about the release of dilating prostaglandins from the endothelial cells.
本研究的目的是确定血管加压素和选择性V2受体激动剂去氨加压素对人隐静脉的影响,特别着重于内皮介导的反应。
从35例接受冠状动脉搭桥手术的患者获取人隐静脉段。将配对的静脉段,一段正常,另一段通过轻柔摩擦去除内皮,安装在器官浴槽中进行张力的等长记录。在存在或不存在V1受体拮抗剂d(CH2)5Tyr (Me)AVP (10(-6) mol/L)、V1-V2受体拮抗剂desGly-d(CH2)5D-Tyr(Et)ValAVP (10(-6) mol/L)、吲哚美辛(10(-6) mol/L)或盐酸NG-硝基-L-精氨酸甲酯(L-NAME, 10(-4) mol/L)的情况下,测定血管加压素和去氨加压素的浓度-反应曲线。
在静息张力下的静脉环中,血管加压素产生浓度依赖性、非内皮依赖性收缩,产生半数最大收缩的血管加压素浓度(EC50)为3.44 x 10(-8) mol/L。血管加压素V1受体拮抗剂(10(-6) mol/L)使血管加压素的对照曲线平行右移9.86倍。在预先用V1拮抗剂(10(-6) mol/L)处理过的预收缩静脉环中,血管加压素引起内皮依赖性舒张。吲哚美辛(10(-6) mol/L)可显著减弱这种舒张,而V1-V2受体拮抗剂(10(-6) mol/L)或L-NAME (10(-4) mol/L)对其无影响。去氨加压素在预收缩静脉环中引起内皮依赖性舒张,这种舒张被V1-V2混合受体拮抗剂和吲哚美辛抑制,但不被V1拮抗剂或L-NAME预处理抑制。
这些观察结果表明,血管加压素通过刺激V1受体对人隐静脉发挥收缩作用。只有在V1受体被阻断时,血管加压素才会引起人隐静脉扩张。这种舒张似乎是由舒张性前列腺素的释放介导的,可能来源于内皮细胞,且不依赖于V2受体刺激或一氧化氮的释放。去氨加压素引起的舒张很大程度上依赖于V2受体刺激,这可能导致内皮细胞释放舒张性前列腺素。